Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Feb-19 9:06 AM View:  | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 30,000 | $235.00 | $7,050,000.00 | (100%) 30.0K to 0 | < 1% |
| 15-Feb-19 9:17 AM View: | Nanda Nisha Chief Development Officer | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 18,896 | $235.00 | $4,440,560.00 | (100%) 18.9K to 0 | < 1% |
| 15-Feb-19 9:16 AM View: | Naider Avi Z. Director | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 111,843 | $235.00 | $26,283,100.00 | (100%) 111.84K to 0 | |
| 15-Feb-19 9:11 AM View: | Flaherty Keith T. Director | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 9,732 | $235.00 | $2,287,020.00 | (100%) 9.73K to 0 | < 1% |
| 15-Feb-19 9:09 AM View: | Elms Steve Director 10% Owner | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition (change in control) | 2,038,920 | $235.00 | $479,145,984.00 | (50%) 4.08M to 2.04M | < 1% |
| 15-Feb-19 9:06 AM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 162,707 | $235.00 | $38,236,100.00 | (84%) 192.71K to 30.0K | < 1% |
| 15-Feb-19 9:18 AM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 15-Feb-19 | Disposition | 19,000 | $235.00 | $4,465,000.00 | (100%) 19.0K to 0 | < 1% |
| 15-Feb-19 9:16 AM View: | Naider Avi Z. Director | Loxo Oncology, Inc. (LOXO) | 31-Jan-19 | Gift | 15,000 | -- | -- | (12%) 126.84K to 111.84K | |
| 17-Dec-18 5:07 PM View: | Naider Avi Z. Director | Loxo Oncology, Inc. (LOXO) | 13-Dec-18 | Market Purchase | 725 | $138.92 | $100,716.00 | < 1% 126.12K to 126.84K | 69% |
| 12-Dec-18 5:17 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Option Exercise | 7,000 | $3.65 | $25,536.00 | 51% 13.7K to 20.7K | |
| 12-Dec-18 5:14 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 12-Dec-18 5:17 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Option Exercise | 4,500 | $13.67 | $61,515.00 | 22% 20.7K to 25.2K | |
| 12-Dec-18 5:12 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Option Exercise | 10,000 | $13.67 | $136,700.00 | 5% 194.41K to 204.41K | |
| 12-Dec-18 5:17 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Market Option Sale (Planned) | 4,500 | $137.35 | $618,080.00 | (18%) 25.2K to 20.7K | (71%) |
| 12-Dec-18 5:14 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Market Option Sale (Planned) | 1,250 | $137.43 | $171,792.00 | (100%) 1.25K to 0 | (71%) |
| 12-Dec-18 5:12 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 11-Dec-18 | Market Option Sale (Planned) | 10,000 | $137.42 | $1,374,240.00 | (5%) 204.41K to 194.41K | (71%) |
| 12-Dec-18 5:12 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Option Exercise | 10,000 | $13.67 | $136,700.00 | 5% 194.41K to 204.41K | |
| 12-Dec-18 5:17 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Market Option Sale (Planned) | 4,500 | $133.65 | $601,434.00 | (25%) 18.2K to 13.7K | (76%) |
| 12-Dec-18 5:14 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Market Option Sale (Planned) | 1,250 | $133.67 | $167,084.00 | (100%) 1.25K to 0 | (76%) |
| 12-Dec-18 5:12 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Market Option Sale (Planned) | 10,000 | $133.52 | $1,335,200.00 | (5%) 204.41K to 194.41K | (76%) |
| 12-Dec-18 5:17 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Option Exercise | 4,500 | $13.67 | $61,515.00 | 33% 13.7K to 18.2K | |
| 12-Dec-18 5:14 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 10-Dec-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 28-Nov-18 5:09 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Market Option Sale (Planned) | 1,250 | $142.28 | $177,850.00 | (100%) 1.25K to 0 | (65%) |
| 28-Nov-18 5:08 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Market Option Sale (Planned) | 10,000 | $141.34 | $1,413,420.00 | (5%) 204.41K to 194.41K | (66%) |
| 28-Nov-18 5:13 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Option Exercise | 4,500 | $8.23 | $37,031.30 | 33% 13.7K to 18.2K | |
| 28-Nov-18 5:09 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 28-Nov-18 5:08 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Option Exercise | 10,000 | $13.67 | $136,700.00 | 5% 194.41K to 204.41K | |
| 28-Nov-18 5:13 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 27-Nov-18 | Market Option Sale (Planned) | 4,500 | $141.66 | $637,481.00 | (25%) 18.2K to 13.7K | (66%) |
| 28-Nov-18 5:13 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Option Exercise | 5,500 | $3.65 | $20,064.00 | 40% 13.7K to 19.2K | |
| 28-Nov-18 5:09 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 28-Nov-18 5:08 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Option Exercise | 39,000 | $2.20 | $85,708.70 | 24% 165.41K to 204.41K | |
| 28-Nov-18 5:13 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Market Option Sale (Planned) | 5,500 | $153.13 | $842,224.00 | (29%) 19.2K to 13.7K | (53%) |
| 28-Nov-18 5:09 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Market Option Sale (Planned) | 1,250 | $153.08 | $191,356.00 | (100%) 1.25K to 0 | (53%) |
| 28-Nov-18 5:08 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 26-Nov-18 | Market Option Sale (Planned) | 10,000 | $153.18 | $1,531,830.00 | (5%) 204.41K to 194.41K | (53%) |
| 05-Oct-18 4:42 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Option Exercise | 10,000 | $3.65 | $36,480.00 | 6% 165.41K to 175.41K | |
| 05-Oct-18 4:46 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Market Option Sale (Planned) | 4,500 | $162.64 | $731,884.00 | (25%) 18.2K to 13.7K | (44%) |
| 05-Oct-18 4:42 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Market Option Sale (Planned) | 2,905 | $162.62 | $472,424.00 | (2%) 175.41K to 172.5K | (44%) |
| 05-Oct-18 4:42 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Market Sale (Planned) | 7,095 | $162.62 | $1,153,820.00 | (4%) 172.5K to 165.41K | (44%) |
| 05-Oct-18 4:44 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Market Option Sale (Planned) | 1,250 | $162.64 | $203,304.00 | (100%) 1.25K to 0 | (44%) |
| 05-Oct-18 4:46 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Option Exercise | 4,500 | $3.65 | $16,416.00 | 33% 13.7K to 18.2K | |
| 05-Oct-18 4:44 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 04-Oct-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 05-Oct-18 4:44 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 03-Oct-18 | Market Option Sale (Planned) | 1,250 | $167.20 | $208,996.00 | (100%) 1.25K to 0 | (40%) |
| 05-Oct-18 4:46 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 03-Oct-18 | Option Exercise | 5,500 | $3.65 | $20,064.00 | 40% 13.7K to 19.2K | |
| 05-Oct-18 4:44 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 03-Oct-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 05-Oct-18 4:46 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 03-Oct-18 | Market Option Sale (Planned) | 5,500 | $167.16 | $919,378.00 | (29%) 19.2K to 13.7K | (40%) |
| 05-Oct-18 4:42 PM View: | Bilenker Joshua H. President & CEO Director | Loxo Oncology, Inc. (LOXO) | 03-Oct-18 | Market Option Sale (Planned) | 7,095 | $168.18 | $1,193,250.00 | (4%) 172.5K to 165.41K | (40%) |
| 03-Oct-18 5:05 PM View: | Kunkel Lori Anne Director | Loxo Oncology, Inc. (LOXO) | 01-Oct-18 | Option Exercise | 5,000 | $3.65 | $18,240.00 | 100% 0 to 5.0K | |
| 03-Oct-18 5:05 PM View: | Kunkel Lori Anne Director | Loxo Oncology, Inc. (LOXO) | 01-Oct-18 | Market Option Sale (Planned) | 5,000 | $170.37 | $851,829.00 | (100%) 5.0K to 0 | (38%) |
| 14-Sep-18 6:19 PM View: | Burstein Jennifer Senior VP of Finance | Loxo Oncology, Inc. (LOXO) | 13-Sep-18 | Option Exercise | 1,250 | $11.35 | $14,187.50 | 100% 0 to 1.25K | |
| 14-Sep-18 6:14 PM View: | van Naarden Jacob Chief Operating Officer | Loxo Oncology, Inc. (LOXO) | 13-Sep-18 | Market Option Sale (Planned) | 4,500 | $165.98 | $746,903.00 | (25%) 18.2K to 13.7K | (41%) |
